Randomized controlled trial to determine the impact of probiotic administration on colonization with multidrug-resistant organisms in critically ill patients

Infection Control and Hospital Epidemiology

Volumn 36, Issue 12, 2015, Pages 1451-1454

  Kwon, Jennie H ^a   Bommarito, Kerry M ^a   Reske, Kimberly A ^a   Seiler, Sondra M ^a   Hink, Tiffany ^a   Babcock, Hilary M ^a   Kollef, Marin H ^a   Fraser, Victoria J ^a   Burnham, Carey Ann D ^a   Dubberke, Erik R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL INFECTION; HEALTH CARE QUALITY; HUMAN; LACTOBACILLUS RHAMNOSUS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PILOT STUDY; POPULATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; CROSS INFECTION; DRUG EFFECTS; GASTROINTESTINAL DISEASES; INTENSIVE CARE UNIT; MIDDLE AGED; MISSOURI; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE; FEMALE; GASTROINTESTINAL DISEASES; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE UNITS; LACTOBACILLUS RHAMNOSUS; MALE; MIDDLE AGED; MISSOURI; PILOT PROJECTS; PROBIOTICS; STANDARD OF CARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958522282     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2015.195     Document Type: Article

References (10)

1. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011;11:30–38.
2. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011;23:47.
3. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004;39:219–226.
4. Hink T, Burnham CA, Dubberke ER. A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. Anaerobe 2013; 19:39–43.
5. de Regt MJ, Willems RJ, Hene RJ, et al. Effects of probiotics on acquisition and spread of multiresistant enterococci. Antimicrob Agents Chemother 2010;54:2801–2805.
6. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382:1249–1257.
7. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst 2013;5:CD006095.
8. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7:59–62.
9. Barraud E, Bollaert PE, Gibot S. Impact of the administration of probiotics on mortality in critically ill adult patients: a metaanalysis of randomized controlled trials. Chest 2013;143:646–655.
10. Petrof EO, Dhaliwal R, Manzanares W, et al. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med 2012;40:3290–3302.